Zenas BioPharma (NASDAQ:ZBIO) Now Covered by Analysts at Morgan Stanley

Posted by Brian Himes on Oct 20th, 2026

Research analysts at Morgan Stanley assumed coverage on shares of Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) in a report released on Tuesday. The firm set an “equal weight” rating and a $32.00 price target on the stock. Morgan Stanley’s price target indicates a potential upside of 13.98% from the company’s previous close.

Several other research firms have also recently weighed in on ZBIO. HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Zenas BioPharma in a report on Tuesday, October 13th. Guggenheim reiterated a “buy” rating and issued a $55.00 price objective on shares of Zenas BioPharma in a research note on Wednesday, September 30th. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Citigroup lifted their target price on shares of Zenas BioPharma from $41.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, September 30th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Zenas BioPharma in a research note on Tuesday, October 6th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.71.

View Our Latest Research Report on Zenas BioPharma

Zenas BioPharma Stock Up 13.0%

ZBIO traded up $3.23 during mid-day trading on Tuesday, reaching $28.07. 10,220 shares of the stock were exchanged, compared to its average volume of 809,270. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. The stock has a market capitalization of $1.83 billion, a PE ratio of -3.11 and a beta of -0.90. The company has a 50 day moving average price of $30.05 and a two-hundred day moving average price of $25.55. Zenas BioPharma has a 1 year low of $13.50 and a 1 year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $15.00 million. As a group, research analysts anticipate that Zenas BioPharma will post -5.81 EPS for the current year.

Hedge Funds Weigh In On Zenas BioPharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZBIO. Quantbot Technologies LP purchased a new position in Zenas BioPharma during the second quarter valued at approximately $49,000. Jupiter Topco LLC purchased a new stake in Zenas BioPharma in the 2nd quarter worth approximately $201,000. The Manufacturers Life Insurance Company purchased a new stake in Zenas BioPharma in the 2nd quarter worth approximately $204,000. Bank of New York Mellon Corp lifted its stake in Zenas BioPharma by 17.5% in the 1st quarter. Bank of New York Mellon Corp now owns 60,864 shares of the company’s stock worth $1,190,000 after purchasing an additional 9,062 shares in the last quarter. Finally, Sei Investments Co. bought a new position in Zenas BioPharma in the 1st quarter valued at $242,000.

Zenas BioPharma Company Profile

(Get Free Report)

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.